Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the wnt signaling pathway. surrozen is founded by four leading edge scientists from stanford university: k. christopher garcia, ph.d.; roel nusse, ph.d.; calvin kuo, m.d., ph.d.; and claudia janda, ph.d. each has conducted extensive research on wnt signaling, with findings that together shape surrozen’s technology and approach to therapeutic development. the company is backed by the column group, a leading biotechnology venture capital firm. we are currently seeking highly creative scientists to join our founding team, and invite you to explore career opportunities on our website. if you don’t find a perfect job match, but think surrozen may be the right place for you, please submit your resume to careers@surrozen.com.Surrozen, Inc. registers 250,000 shares of its common stock, par value $0.0001 per share, to be issued under the Surrozen, Inc. 2025 Equity Inducement Plan. The registration statement incorporates the company’s prior annual, proxy, quarterly and current reports by reference so that those documents form part of the disclosure for the plan.
The filing reiterates that the company provides contractual indemnification to directors and officers under Delaware law, maintains indemnification agreements and standard directors-and-officers insurance, and includes the 2025 Plan and related legal and auditor consents as exhibits.
Surrozen reported a cash position of $90.4 million and returned a net income of $39.7 million for the three months ended June 30, 2025, and $12.8 million for the six‑month period, driven largely by noncash fair‑value changes in a tranche liability and warrant liabilities. Operating activities used $15.4 million of cash in the first half of 2025 while the company recorded a consolidated accumulated deficit of approximately $272.5 million. In March 2025 Surrozen completed the first tranche of a two‑tranche private placement (the 2025 PIPE), raising net proceeds of about $71.2 million from the first closing and issuing 5.2 million shares, pre‑funded warrants and Series E warrants; the second tranche is contingent on FDA clearance of an IND for SZN‑8141. Warrant liabilities and a remaining tranche liability create significant noncash volatility: warrant liabilities were reported at $32.6 million and the tranche liability at $10.9 million as of June 30, 2025. Management believes existing cash is sufficient for at least 12 months, but the company expects continued R&D spending and may need additional capital to advance its pipeline.
Surrozen, Inc. reported by way of a Current Report on Form 8-K that on August 8, 2025 it issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to the 8-K as Exhibit 99.1 and the filing also includes the Cover Page Interactive Data File (Exhibit 104). The company notes that the information in Item 2.02 and the attached exhibit is not deemed to be "filed" for Section 18 purposes and will not be incorporated by reference into other filings under the Securities Act.
The report lists the company as an emerging growth company and confirms securities registered on Nasdaq: Common Stock (SRZN) and Redeemable warrants (SRZNW). The document is signed by Charles Williams, Chief Financial Officer, Chief Operating Officer and Corporate Secretary.
FAQ
What is the current stock price of Surrozen (SRZNW)?
